Ligand Pharmaceuticals (LGND) Profit After Tax Growth (1y) (2011 - 2026)
Ligand Pharmaceuticals (LGND) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
PAT Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
66.06% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
17.05% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
-129.68% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-290.15% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-632.44% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Ligand Pharmaceuticals |
5.47 Bn |
4.69 Bn |
48.45 Mn |
68.56% |
| Date | Value |
|---|
| Mar 31, 2026 |
68.56% |
| Dec 31, 2025 |
244.06% |
| Sep 30, 2025 |
1,735.15% |
| Jun 30, 2025 |
109.34% |
| Mar 31, 2025 |
-149.28% |
| Dec 31, 2024 |
-256.59% |
| Sep 30, 2024 |
30.19% |
| Jun 30, 2024 |
-2,366.86% |
| Mar 31, 2024 |
105.34% |
| Dec 31, 2023 |
213.54% |
| Sep 30, 2023 |
-2,642.82% |
| Jun 30, 2023 |
355.87% |
| Mar 31, 2023 |
372.66% |
| Dec 31, 2022 |
-222.78% |
| Sep 30, 2022 |
-98.01% |
| Jun 30, 2022 |
-102.91% |
| Mar 31, 2022 |
-184.97% |
| Dec 31, 2021 |
-194.03% |
| Sep 30, 2021 |
403.51% |
| Jun 30, 2021 |
39.12% |
